Perspective Therapeutics Inc (CATX)
2.645
-0.06
(-2.40%)
USD |
NYAM |
Oct 09, 16:00
2.645
0.00 (0.00%)
After-Hours: 16:09
Perspective Therapeutics EPS Diluted (Quarterly) : -0.222 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.222 |
| March 31, 2026 | -0.2528 |
| December 31, 2025 | -0.5043 |
| September 30, 2025 | -0.3495 |
| June 30, 2025 | -0.2894 |
| March 31, 2025 | -0.2512 |
| December 31, 2024 | -0.5684 |
| September 30, 2024 | -0.2141 |
| June 30, 2024 | -0.1756 |
| March 31, 2024 | -0.2481 |
| September 30, 2023 | -0.3691 |
| June 30, 2023 | -0.3967 |
| March 31, 2023 | -0.0162 |
| June 30, 2022 | -0.1463 |
| March 31, 2022 | -0.0948 |
| December 31, 2021 | -0.113 |
| September 30, 2021 | -0.1581 |
| June 30, 2021 | -0.0749 |
| March 31, 2021 | -0.0608 |
| December 31, 2020 | -0.1045 |
| September 30, 2020 | -0.1039 |
| June 30, 2020 | -0.175 |
| March 31, 2020 | -0.0811 |
| December 31, 2019 | -0.1334 |
| September 30, 2019 | -0.1215 |
| Date | Value |
|---|---|
| June 30, 2019 | -0.163 |
| March 31, 2019 | -0.1678 |
| December 31, 2018 | -0.2103 |
| September 30, 2018 | -0.2284 |
| June 30, 2018 | -0.40 |
| March 31, 2018 | -0.20 |
| December 31, 2017 | -0.30 |
| September 30, 2017 | -0.30 |
| June 30, 2017 | -0.30 |
| March 31, 2017 | -0.20 |
| December 31, 2016 | -0.30 |
| September 30, 2016 | -0.30 |
| June 30, 2016 | -0.20 |
| March 31, 2016 | -0.20 |
| December 31, 2015 | -0.20 |
| September 30, 2015 | -0.20 |
| June 30, 2015 | -0.20 |
| March 31, 2015 | -0.20 |
| December 31, 2014 | -0.20 |
| September 30, 2014 | -0.10 |
| June 30, 2014 | -0.3072 |
| March 31, 2014 | -0.50 |
| December 31, 2013 | -0.20 |
| September 30, 2013 | -0.60 |
| June 30, 2013 | -0.2894 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Biogen, Inc. | 0.6557 |
| Rigel Pharmaceuticals, Inc. | 0.8835 |
| Enanta Pharmaceuticals, Inc. | -0.6704 |
| Insight Molecular Diagnostics, Inc. | -0.3064 |
| BridgeBio Pharma, Inc. | -0.7775 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -26.98M |
| Revenue (Quarterly) | 0.081M |
| Total Expenses (Quarterly) | 27.06M |
| Enterprise Value | 76.26M |
| Gross Profit Margin (Quarterly) | -1.31K% |
| Profit Margin (Quarterly) | -33.31K% |
| Earnings Yield | -50.23% |
| Normalized Earnings Yield | -46.67 |